Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease
Authors:
- 1 September 2008
- journal article
- Published by Taylor & Francis in Journal of the Operational Research Society
- Vol. 59 (9) , 1173-1181
Abstract
A discrete event simulation model of the patient pathways in the treatment of coronary heart disease (CHD) was used to quantify the health gains and costs associated with increasing secondary prevention drugs prescription for patients with CHD based on the level recommended in the National Service Framework for the UK. A Gompertz distribution was sampled for time to failure (death or non-fatal heart attack). The time to failure was modified in relation to the reduced risk of failure for those on the relevant drugs. The results from the model were validated against national data. Increasing the levels of prescription of secondary prevention drugs to those patients with CHD might prevent 100 deaths per million population per year and cost an additional £4 million per million population per year. With cost per life year saved of £5520, this appears good value for money compared with other health technologies.Keywords
This publication has 16 references indexed in Scilit:
- Choice of modelling technique for evaluating health care interventionsJournal of the Operational Research Society, 2007
- Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarctionEmergency Medicine Journal, 2006
- Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary preventionBMJ, 2005
- Incidence of coronary heart disease in a health authority in London: review of a community registerBMJ, 2003
- The natural history of prevalent ischaemic heart disease in middle-aged menEuropean Heart Journal, 2000
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patientsThe Lancet, 2000
- beta Blockade after myocardial infarction: systematic review and meta regression analysisBMJ, 1999
- The analysis of survival (mortality) data: Fitting Gompertz, Weibull, and logistic functionsMechanisms of Ageing and Development, 1994
- Modelling patient flows and resource provision in health systemsOmega, 1994
- Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham populationAmerican Heart Journal, 1986